1-20 of 15,946 results for subject:Cancer
Librarians' tools
- Search time
- 0.37 seconds
- Solr query time
- 0.026 seconds
- Search query
- subject:Cancer
- We searched for
- subject_t:Cancer OR subject_t:Oncology OR subject_t:Sarcoma OR subject_ses:8937
Type
House
Session
More
Year
More
Department
More
Member
More
Primary member
More
Answering member
More
Legislative stage
Legislation
More
Subject
More
Publisher
To ask the Secretary of State for Health and Social Care, what steps she is taking to meet cancer waiting-time targets.
To ask the Secretary of State for Health and Social Care, what steps she is taking to meet cancer waiting-time targets.
I refer the Hon Member to the answer provided on 7 September in response to Question 19221.
To ask the Secretary of State for Health and Social Care, what steps she is taking to reduce the time between urgent GP referrals and cancer treatment.
To ask the Secretary of State for Health and Social Care, what steps she is taking to reduce the time between urgent GP referrals and cancer treatment.
I refer the Hon Member to the answer provided on 7 September in response to Question 19221.
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to improve access to post-treatment pathways within cancer treatment.
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to improve access to post-treatment pathways within cancer treatment.
I refer the Hon. Member to the Department’s strategy on Living with and Beyond Cancer in Chapter 4 of the National Cancer Plan which examines these and other issues in detail. The plan is available at the following link:
https://www.gov.uk/government/publications/national-cancer-plan-for-england
To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the reasons why approximately one in four bowel cancer cases are diagnosed following an emergency presentation.
To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the reasons why approximately one in four bowel cancer cases are diagnosed following an emergency presentation.
I refer the Hon. Member to the answer provided on 8 July in response to Question 3363.
To ask the Chancellor of the Exchequer, what discussions the Treasury has had with the Financial Conduct Authority and the travel insurance industry about the affordability and availability of travel insurance for people with a history of cancer; and whether the Government will assess the merits of introducing a time-limited...
To ask the Chancellor of the Exchequer, what discussions the Treasury has had with the Financial Conduct Authority and the travel insurance industry about the affordability and availability of travel insurance for people with a history of cancer; and whether the Government will assess the merits of introducing a time-limited...
The Government recognises the importance of ensuring that consumers, including people with a history of cancer, can access suitable travel insurance products, and will consider the proposal referred to. More broadly, HM Treasury has regular engagement with the Financial Conduct Authority (FCA) and industry on a wide range of financial services issues.
The Government is determined that insurers should treat customers fairly and firms are required to do so under FCA rules. The FCA also requires travel insurers to signpost consumers with pre-existing medical conditions to specialist providers where they are declined cover, offered cover with an exclusion, or charged a significantly higher premium.
To ask the Secretary of State for Health and Social Care, what steps NHS England has taken to implement section 3 of the Rare Cancers Act 2026; and when those arrangements are expected to be operational.
To ask the Secretary of State for Health and Social Care, what steps NHS England has taken to implement section 3 of the Rare Cancers Act 2026; and when those arrangements are expected to be operational.
I refer the Hon Member to the answer provided on 6 July in response to Question HL1354, which sets out the steps the Government is taking to implement the Rare Cancers Act.
The Department is rolling out each element of the National Cancer Plan in line with the timetable we set out in February, and we will report back to Parliament in the normal way in due course on the progress made in implementing the action plan, and the resulting outcomes achieved.
To ask the Secretary of State for Health and Social Care, what arrangements have been put in place under section 2 of the Rare Cancers Act 2026 to enable potential participants in rare cancer clinical trials to be identified and contacted.
To ask the Secretary of State for Health and Social Care, what arrangements have been put in place under section 2 of the Rare Cancers Act 2026 to enable potential participants in rare cancer clinical trials to be identified and contacted.
I refer the Hon Member to the answer provided on 6 July in response to Question HL1354, which sets out the steps the Government is taking to implement the Rare Cancers Act.
The Department is rolling out each element of the National Cancer Plan in line with the timetable we set out in February, and we will report back to Parliament in the normal way in due course on the progress made in implementing the action plan, and the resulting outcomes achieved.
To ask the Secretary of State for Health and Social Care, in how many NHS Genomic Laboratory Hubs potential genomic targets for experimental cancer therapies are reported as part of routine genomic testing; what proportion of eligible cancer patients received such reporting in the most recent reporting period; and what...
To ask the Secretary of State for Health and Social Care, in how many NHS Genomic Laboratory Hubs potential genomic targets for experimental cancer therapies are reported as part of routine genomic testing; what proportion of eligible cancer patients received such reporting in the most recent reporting period; and what...
I refer the Hon Member to the answer provided on 6 July in response to Question HL1354, which sets out the steps the Government is taking to implement the Rare Cancers Act.
The Department is rolling out each element of the National Cancer Plan in line with the timetable we set out in February, and we will report back to Parliament in the normal way in due course on the progress made in implementing the action plan, and the resulting outcomes achieved.
To ask the Secretary of State for Health and Social Care, what milestones have been completed against the National Cancer Plan commitment to report potential genomic targets for experimental cancer therapies as part of routine genomic testing upfront in the patient pathway; what milestones remain outstanding; and what timelines have...
To ask the Secretary of State for Health and Social Care, what milestones have been completed against the National Cancer Plan commitment to report potential genomic targets for experimental cancer therapies as part of routine genomic testing upfront in the patient pathway; what milestones remain outstanding; and what timelines have...
I refer the Hon Member to the answer provided on 6 July in response to Question HL1354, which sets out the steps the Government is taking to implement the Rare Cancers Act.
The Department is rolling out each element of the National Cancer Plan in line with the timetable we set out in February, and we will report back to Parliament in the normal way in due course on the progress made in implementing the action plan, and the resulting outcomes achieved.
To ask the Secretary of State for Health and Social Care, what steps she is taking to improve cancer diagnosis and treatment.
To ask the Secretary of State for Health and Social Care, what steps she is taking to improve cancer diagnosis and treatment.
I refer my Hon Friend to the answers provided on this issue in the session of departmental oral questions held on 20 October 2026.
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to ensure that forthcoming NHS procurement frameworks for wigs and breast prostheses meet the needs of Black and global majority cancer patients.
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to ensure that forthcoming NHS procurement frameworks for wigs and breast prostheses meet the needs of Black and global majority cancer patients.
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to help support access to appropriate wigs and breast prostheses for people undergoing cancer treatment.
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to help support access to appropriate wigs and breast prostheses for people undergoing cancer treatment.
To ask the Secretary of State for Health and Social Care, what discussions her Department has had with NHS England and NHS Supply Chain on ensuring access to wigs suitable for Afro-textured hair and breast prostheses across a range of skin tones.
To ask the Secretary of State for Health and Social Care, what discussions her Department has had with NHS England and NHS Supply Chain on ensuring access to wigs suitable for Afro-textured hair and breast prostheses across a range of skin tones.
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to ensure adequate access to wigs and breast prostheses across NHS trusts and integrated care boards.
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to ensure adequate access to wigs and breast prostheses across NHS trusts and integrated care boards.
To ask His Majesty's Government which bodies or officeholders are accountable for (1) collecting, (2) reporting, and (3) publishing data on (a) expenditure on brain tumours, including direct disease-specific research expenditure, (b) molecular profiling, (c) liquid biopsy testing, (d) treatment and clinical trial matching, (e) international trial participation, and (f)...
To ask His Majesty's Government which bodies or officeholders are accountable for (1) collecting, (2) reporting, and (3) publishing data on (a) expenditure on brain tumours, including direct disease-specific research expenditure, (b) molecular profiling, (c) liquid biopsy testing, (d) treatment and clinical trial matching, (e) international trial participation, and (f)...
Responsibility for the delivery of cancer services and the achievement of cancer outcomes sits with NHS England and local National Health Service organisations. The Department of Health and Social Care (DHSC) and its research partners support the evidence base, while NHS England is responsible for service delivery and improvement. Government responsibility for delivering cancer research is shared between DHSC, with research delivered by the National Institute for Health and Care Research (NIHR), and the Department for Science, Innovation and Technology, with research delivered via UK Research and Innovation.
The DHSC holds data on participation in brain tumour research studies on the NIHR Research Delivery Network portfolio but does not hold data on participation in international trials. On the other data requests contained in the Noble Lord’s questions, I refer him to the answer provided in the House of Lords on 14 September in response to Question HL3172, which, for ease of reference, is reproduced below:
“I refer the Noble Lord Hunt to the answers provided on 15 July in response to Question HL1677 and 16 July in response to Question HL1674. Further to the answer provided on 15 July in response to Question HL1677, over eight years, from 2018/19 to 2025/26, UK Research and Innovation (UKRI) committed £66.3 million to brain tumour research. UKRI also supported 93 studentships over this period. All associated work packages for the National Institute for Health and Care Research Brain Tumour Research Consortium have now been fully executed. The information requested is not held by the Medicines and Healthcare products Regulatory Agency. Information on trials supported through the Cancer Vaccine Launch Pad (CVLP) can be found on their website. The platform is designed to be company and clinical trial agnostic so any company can contact the CVLP to explore how the platform can support their research. Other information is not available as it is not held in the format requested or is not held centrally.”
To ask His Majesty's Government which bodies or officeholders are accountable for figures relating to (1) expenditure on brain tumour research, (2) tumour-specific expenditure, (3) molecular testing and subsequent treatment or clinical trial matching, (4) participation in international clinical trials, and (5) patient outcomes; and where such figures are not...
To ask His Majesty's Government which bodies or officeholders are accountable for figures relating to (1) expenditure on brain tumour research, (2) tumour-specific expenditure, (3) molecular testing and subsequent treatment or clinical trial matching, (4) participation in international clinical trials, and (5) patient outcomes; and where such figures are not...
Responsibility for the delivery of cancer services and the achievement of cancer outcomes sits with NHS England and local National Health Service organisations. The Department of Health and Social Care (DHSC) and its research partners support the evidence base, while NHS England is responsible for service delivery and improvement. Government responsibility for delivering cancer research is shared between DHSC, with research delivered by the National Institute for Health and Care Research (NIHR), and the Department for Science, Innovation and Technology, with research delivered via UK Research and Innovation.
The DHSC holds data on participation in brain tumour research studies on the NIHR Research Delivery Network portfolio but does not hold data on participation in international trials. On the other data requests contained in the Noble Lord’s questions, I refer him to the answer provided in the House of Lords on 14 September in response to Question HL3172, which, for ease of reference, is reproduced below:
“I refer the Noble Lord Hunt to the answers provided on 15 July in response to Question HL1677 and 16 July in response to Question HL1674. Further to the answer provided on 15 July in response to Question HL1677, over eight years, from 2018/19 to 2025/26, UK Research and Innovation (UKRI) committed £66.3 million to brain tumour research. UKRI also supported 93 studentships over this period. All associated work packages for the National Institute for Health and Care Research Brain Tumour Research Consortium have now been fully executed. The information requested is not held by the Medicines and Healthcare products Regulatory Agency. Information on trials supported through the Cancer Vaccine Launch Pad (CVLP) can be found on their website. The platform is designed to be company and clinical trial agnostic so any company can contact the CVLP to explore how the platform can support their research. Other information is not available as it is not held in the format requested or is not held centrally.”
To ask the Secretary of State for Health and Social Care, what exemptions, alternative supply arrangements, and clinical provisions are being put in place to ensure that completely unfortified staple foods remain available and accessible to cancer patients, cancer survivors, and other groups who may be advised to limit their...
To ask the Secretary of State for Health and Social Care, what exemptions, alternative supply arrangements, and clinical provisions are being put in place to ensure that completely unfortified staple foods remain available and accessible to cancer patients, cancer survivors, and other groups who may be advised to limit their...
I refer the Hon. Members to the answer provided on 15 September in response to Question 27169 and to the answer provided on 17 July in response to Question 17728.
The Scientific Advisory Committee on Nutrition (SACN) has not published additional assessments on the issues stated since 2017 but retains folic acid on its watching brief. Individuals with medical conditions or concerns about their folic acid intake should seek advice from a healthcare professional.
The Government will evaluate the impact of the policy in the normal way. Details of this evaluation were discussed at the SACN meeting in June 2026 and are provided in SACN’s matters arising and Government updates document provided on the SACN webpage:
https://app.box.com/s/ivrivaemf7fgeo9a17xdmv167c4uvteu/file/2276350423101
To ask the Secretary of State for Health and Social Care, whether the evaluation of mandatory folic acid fortification will separately assess people with a current or previous cancer diagnosis, including effects on cancer progression, recurrence and survival, as distinct from cancer incidence in the general population; what evidence it...
To ask the Secretary of State for Health and Social Care, whether the evaluation of mandatory folic acid fortification will separately assess people with a current or previous cancer diagnosis, including effects on cancer progression, recurrence and survival, as distinct from cancer incidence in the general population; what evidence it...
Like you, Mr Speaker, I have recollections of Aberfan and being at primary school myself at that time.
Too many patients are suffering because of treatment delays and having their cancers missed. My private Member’s Bill, the Cancer (Reporting and Strategy) Bill, would require annual reports to Parliament on cancer diagnosis, outcomes and delivery. Will the Prime Minister commit to supporting this Bill to ensure that his Government and all future Governments are held to account by this House for improving cancer diagnosis and outcomes?
Like you, Mr Speaker, I have recollections of Aberfan and being at primary school myself at that time.
Too many patients are suffering because of treatment delays and having their cancers missed. My private Member’s Bill, the Cancer (Reporting and Strategy) Bill, would require annual reports to Parliament on cancer diagnosis, outcomes and delivery. Will the Prime Minister commit to supporting this Bill to ensure that his Government and all future Governments are held to account by this House for improving cancer diagnosis and outcomes?
I thank the hon. Gentleman for his question and recognise his sincerity and personal experience in this regard. We have a national cancer plan to drive the improvements that he calls for. As part of that, we are also establishing an independent national cancer board, which I will ask to look at his proposal. Last week I met Archie Goodburn, with the Health Secretary, to look at how we can make the UK a world leader in trials for brain cancer treatments. There is huge progress, but we can work with him to deliver more.
I thank the hon. Gentleman for his question and recognise his sincerity and personal experience in this regard. We have a national cancer plan to drive the improvements that he calls for. As part of that, we are also establishing an independent national cancer board, which I will ask to look at his proposal. Last week I met Archie Goodburn, with the Health Secretary, to look at how we can make the UK a world leader in trials for brain cancer treatments. There is huge progress, but we can work with him to deliver more.
I thank the hon. Gentleman for his question and recognise his sincerity and personal experience in this regard. We have a national cancer plan to drive the improvements that he calls for. As part of that, we are also establishing an independent national cancer board, which I will ask to look at his proposal. Last week I met Archie Goodburn, with the Health Secretary, to look at how we can make the UK a world leader in trials for brain cancer treatments. There is huge progress, but we can work with him to deliver more.
Like you, Mr Speaker, I have recollections of Aberfan and being at primary school myself at that time.
Too many patients are suffering because of treatment delays and having their cancers missed. My private Member’s Bill, the Cancer (Reporting and Strategy) Bill, would require annual reports to Parliament on cancer diagnosis, outcomes and delivery. Will the Prime Minister commit to supporting this Bill to ensure that his Government and all future Governments are held to account by this House for improving cancer diagnosis and outcomes?